Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

(2011) T Yokota et al.   BRITISH JOURNAL OF CANCER

Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features

(2010) Pei Woon Ang et al.   BMC CANCER

The Role of the CpG Island Methylator Phenotype in Colorectal Cancer Prognosis Depends on Microsatellite Instability Screening Status

(2010) A. M. Dahlin et al.   CLINICAL CANCER RESEARCH

Role of the Serrated Pathway in Colorectal Cancer Pathogenesis

(2010) Barbara Leggett et al.   GASTROENTEROLOGY

Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation

(2010) Sun Lee et al.   PATHOLOGY INTERNATIONAL

Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma

(2010) Xiao-Dong Bu   WORLD JOURNAL OF GASTROENTEROLOGY

KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy

(2009) Ahmad D. Siddiqui et al.   ANNALS OF SURGICAL ONCOLOGY

Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer

(2009) Pierre Laurent-Puig et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations in Both KRAS and BRAF May Contribute to the Methylator Phenotype in Colon Cancer

(2008) Takeshi Nagasaka et al.   GASTROENTEROLOGY

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

(2008) S. Ogino et al.   GUT

Distinct CpG island methylation profiles andBRAFmutation status in serrated and adenomatous colorectal polyps

(2008) Yong Ho Kim et al.   INTERNATIONAL JOURNAL OF CANCER

Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample

(2008) Katsuhiko Nosho et al.   PLoS One